- Poster presentation
- Open Access
Influence of TNFα–308 and T676G TNF-RII polymorphism on response to etanercept and posibility to discontinue tretment
© Vojinovic et al; licensee BioMed Central Ltd. 2011
- Published: 14 September 2011
- Disease Subtype
- Genotype Polymorphism
- Etanercept Therapy
- Etanercept Treatment
Genetic contribution of TNFὰ–308 promoter and T676G TNF-RII polymorphism on response to TNF-blocking agents in JIA is not yet well established.
Genomic DNA was extracted and TNFὰ–308 promoter and T676G TNF-RII polymorphism was evaluated using the PCR-RFLP method in 60 JIA patients treated with etanercept. Time cut of point for outcome data analysis was 4 years.
JIA patients with GG TNFὰ308 genotype can achieve better outcome and etanercept treatment can be stopped earlier compared to GA genotype patients who need two years of treatment to achieve same results. TNFὰ308 genotype could be useful clinical predictive biomarker for treatment response in all disease subtypes except systemic and RF positive JIA.
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.